|Bid||0.281500 x 300|
|Ask||0.290000 x 4000|
|Day's Range||0.2600 - 0.2800|
|52 Week Range||0.1720 - 1.4500|
|Beta (3Y Monthly)||-0.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.65|
HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Below are several companies positioning themselves to be a viable opioid alternative. We are highlighting: Endonovo Therapeutics, Inc. (ENDV), INSYS Therapeutics, ...
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Titan Pharmaceuticals, Inc. (TTNP) reported third quarter 2018 results on November 14th in a press release and in a subsequently filed 10-Q. During the period, Titan recorded total revenues of $1.7 million compared to $40 thousand in 3Q:17. The $244,000 in Titan-generated Probuphine sales compares to 2Q:18’s $75,000, which was for a partial period.
The San Francisco-based company said it had a loss of 11 cents per share. The specialty pharmaceutical company posted revenue of $1.7 million in the period. In the final minutes of trading on Wednesday, ...
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing and commercializing proprietary therapeutics for the treatment of select chronic ...
Management Team to Host Conference Call Nov. 14 at 4:15 p.m. EST / 1:15 p.m. PST SOUTH SAN FRANCISCO, Calif. , Nov. 8, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing ...
HENDERSON, NV / ACCESSWIRE / November 7, 2018 / Midterm elections are expected to result in a split Congress, which should increase predictability for the biotech industry, and prevent, what some see as disruptive, government dictated pricing, less likely than if there is a Congress controlled by one party. Propanc Biopharma, Inc. (PPCB) is one biotech firm you should look at today. The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer.
CORAL GABLES, FL / ACCESSWIRE / November 5, 2018 / Healthcare companies are taking a new and novel approach the health tech in the form of new innovation that takes the guesswork out of tracking health & reporting results. Furthermore, new digital screening technology is allowing both patients and physicians to better understand many different health issues, more clearly. Things like Wireless Healthcare are highly ambitious with the presence of various players with current and future market outlook in the developed and emerging markets.
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / Conatus Pharmaceuticals and Titan Pharmaceuticals were both seeing gains in Friday’s trading session. There was no news to explain Titan shares jumping but Conatus reported third quarter results and an update on its trials last week. Conatus Pharmaceuticals Inc. shares closed up 19.63% on about 1.8 million shares traded on Friday.
CORAL GABLES, FL / ACCESSWIRE / November 2, 2018 / Over the last few days, prices of the iShares Nasdaq Biotech ETF (IBB) as well as the SPDR Healthcare ETF (XLV) have recovered from previous lows this week. Premier Health Group, Inc. (PHGRF)(PHGI.CN) saw its shares trade higher on Thursday. Shares of Premier Health Group, Inc. (PHGRF)(PHGI.CN) have begun to trade on the OTC Markets Group Inc.'s OTCQB Venture Market in the United States, under the symbol PHGRF in late October, and are now Depository Trust Company eligible, effective Oct. 22, 2018.
CORAL GABLES, FL / ACCESSWIRE / October 30, 2018 / According to the MarketsAndMarkets* report "Healthcare IT Market by Product (EHR, RIS, PACS, VNA, CPOE, HIE, Telehealth, Healthcare Analytics, Population Health Management, Supply Chain Management, CRM, Fraud Management, Claims Management) End User (Provider, Payer) - Global Forecast to 2021", the market for healthcare IT is expected to reach $280.25 Billion by 2021 at a CAGR of 15.9% during the forecast period. HealthVue is a group of four Greater Vancouver-based fully integrated, paperless and electronic-medical-record-based medical clinics with a 10-year history, 22 healthcare professionals and over 100,000 active patients.
Knight Therapeutics Inc. (GUD.TO) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today the commercial availability of PROBUPHINE™ (buprenorphine hydrochloride subdermal implant), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support1. Knight has the exclusive right to distribute PROBUPHINE in Canada under a license agreement with Titan Pharmaceuticals, Inc. (TTNP).
Believe it or not, there are stocks focusing on healthcare that have managed to hit new highs this month including Premier Health Group, Inc. (PHGRF)(PHGI.CN), Titan Pharmaceuticals (TTNP), and Amneal Pharmaceuticals Inc. (AMRX). Premier Health Group, Inc. (PHGRF)(PHGI.CN), has managed to hit trading levels as high as CAD$0.88 this month. The company announced that just this week its common shares that are traded on the OTC Markets Group Inc.'s OTCQB Venture Market in the United States, under the symbol "PHGRF," are now Depository Trust Company eligible.
NEW YORK, NY / ACCESSWIRE / October 22, 2018 / U.S. equities finished mostly lower on Friday as earlier gains due to upbeat corporate earnings were hamstrung by a weakness in housing sales. According to ...
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP), a commercial stage company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today announced the appointment of Dane D. Hallberg to the newly created position of Executive Vice President and Chief Commercial Officer, effective immediately. Mr. Hallberg will be responsible for leading all of the company's commercial activities. "Dane brings to Titan important experience and depth of knowledge in sales and marketing, product launch and market access as we relaunch Probuphine and work to maximize this commercial opportunity," said Titan's President and CEO, Sunil Bhonsle.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) ("Titan" or the "Company"), a commercial stage company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today announced the pricing of an underwritten public offering with expected total gross proceeds of $9,500,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) Class A Units consisting of 5,100,000 shares of our Common Stock and Warrants to purchase 5,100,000 shares of Common Stock, and (ii) Class B Units consisting of 8,225 shares of our Series A Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into an aggregate of 32,900,000 shares of Common Stock, and Warrants exercisable for the number of shares of Common Stock into which the shares of Series A Convertible Preferred Stock are convertible.
If you want to know who really controls Titan Pharmaceuticals Inc (NASDAQ:TTNP), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions asRead More...
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has been awarded a two year grant of approximately $6.7 million from the National Institutes of Health's National Institute on Drug Abuse (NIDA) for the development of a ProNeura™ based six-month implantable formulation of Nalmefene, an opioid antagonist, intended for the prevention of relapse to opioid addiction, following opioid detoxification. The grant provides approximately $2.7 million for the project from now through August 31, 2019, with the balance to be funded over the subsequent year, subject to satisfactory project progress, fund availability and certain other conditions. "NIDA previously provided funds for an important Phase 3 trial of our approved product, Probuphine®, and we are grateful for this additional vote of confidence in our ProNeura technology as well as our ability to execute on another program for the treatment of opioid addiction," said Titan's Chief Scientific Officer and Principal Investigator of the project, Dr. Kate DeVarney.
The San Francisco-based company said it had a loss of 4 cents per share. The specialty pharmaceutical company posted revenue of $2.7 million in the period. In the final minutes of trading on Tuesday, the ...
SOUTH SAN FRANCISCO, Calif. , Aug. 14, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing ...
SOUTH SAN FRANCISCO, Calif., Aug. 3, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) announced today that it has entered into an amendment (the "Amendment") of the previously announced definitive asset purchase, supply and support agreement (the "Purchase Agreement") with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. through which Molteni acquired the European intellectual property related to Probuphine®. Under the Amendment, Molteni will make an immediate payment to Titan of €950,000 (approx. $1.1 million), and has committed to make a convertible loan to Titan of €550,000 (approx. $0.6 million) in mid-September subject to Titan's submission, in accordance with the Amendment, of a response to questions posed by the European Medicines Agency (EMA), in exchange for the elimination of an aggregate of €2.0 million (approx. $2.3 million) of regulatory milestones provided for in the Purchase Agreement, which would be payable potentially in 2019 at the earliest.
SAN FRANCISCO , July 2, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ ...